Moving the HME Industry Forward

Manufacturer/Provider

Medtrade Exhibitor News – New Chairman at Invacare

May 18, 2015

ELYRIA, OH – Shareholders at Invacare Corp have elected Matthew E. Monaghan as the Ohio-based company’s new chairman of the board. Clifford D. Nastas, a director of the Dan T. Moore Company and president of a group of its automotive and advanced materials operating companies, was also named to the Board. Dr. C. Martin Harris, who had been serving as Interim Chairman, will return to his role as independent lead director.

”We are pleased to welcome Matt and Cliff to the Invacare Board of Directors,” said Dr. Harris. ”Matt has deep cross-functional business experience in the medical device industry, and we believe he is the best person to lead the Company both as CEO and Chairman of the Board. We also look forward to benefiting from Cliff’s extensive business leadership and management expertise, which includes experience as the CEO of a publicly-traded Company.”

”I am honored to be named Chairman of Invacare’s Board of Directors,” said Mr. Monaghan. ”I believe Invacare is well positioned to take advantage of the growing opportunities in the home health and long-term care channels. I look forward to working closely with the Board of Directors, and I would like to thank Dr. Harris for his contributions as Interim Chairman over the past several months.”

ResMed Updates Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart Failure
SAN DIEGO – ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.

The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure (based on a hazard ratio [HR] = 1.136, 95 percent confidence interval [95% CI] = (0.974, 1.325), p-value = 0.104). The results from SERVE-HF are preliminary and will be submitted for future publication after further analysis.